2 results
Approved WMORecruiting
Primary Objective:Part 1 Dose Escalation• To investigate the safety and tolerability of LAVA-051 in patients with relapsed/refractory CLL, MM, or AML. • To determine the RP2D of LAVA-051 in patients with relapsed/refractory CLL, MM or AML.Part 2…
Approved WMORecruiting
This study is an open-label, non-randomized extension to study CCDZ173X2201. It aims to provide treatment with CDZ173 to patients withAPDS/PASLI who participated in study CCDZ173X2201 or who were treated previously with PI3Kδ inhibitors other than…